GlassScriptPhysician profile
Angela K Quick
NPI 1760953418
$9,903.14
in general payments reported to CMS, 2019-2025
46 companies · $2,597 in 2025
The $2,597 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,131 · 2022: $895 · 2023: $2,226 · 2024: $3,054 · 2025: $2,597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,793 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,793.06 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,854.98 | 2021-2025 | |
| Janssen Biotech, INC. | $929.26 | 2022-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $918.30 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $719.00 | 2022-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $509.42 | 2022-2025 | Epclusa |
| Genzyme Corporation | $425.32 | 2023-2025 | |
| Lilly USA, LLC | $422.18 | 2021-2025 | Omvoh |
| Qol Medical, LLC | $368.85 | 2023-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $341.69 | 2024-2025 | Rezdiffra, Resmetirom |
| E.R. Squibb & Sons, L.L.C. | $236.28 | 2023-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $179.84 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $160.30 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $153.00 | 2022-2025 | Linzess |
| Ardelyx, INC. | $145.67 | 2023-2025 | Ibsrela |
| Celgene Corporation | $136.38 | 2022-2024 | Zeposia |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Quick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.